Evidence map›Paper›PMID 40903625›Full record

Trial reportClinical and experimental nephrology2025

Sodium glucose co-transporter 2 inhibitors (SGLT2Is) effect on erectile dysfunction (ED) in patients with chronic kidney disease (CKD).

Amr Mohamed Shaker, Nehal Kamal Rakha, Ahmed Keshk, Usama A Sharaf El Din

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amr Mohamed ShakerNephrology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt. amr.shaker@kasralainy.edu.eg.
Nehal Kamal RakhaNephrology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Ahmed KeshkAndrology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Usama A Sharaf El DinNephrology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundED is commonly encountered among male CKD patients. SGLT2Is were recently recommended as a universal treatment for CKD. It's hypothesized that the mechanism of action of SGLT2Is could be related to improving endothelial dysfunction. So, patients with ED due to CKD might benefit from adding SGLT2Is to their management. We aimed to study the effect of SGLT2Is on ED in CKD patients.

methodsAfter complete clinical examination and laboratory investigations needed to exclude other causes of ED, 34 CKD cases were randomly assigned to receive either empagliflozin (Empa) or dapagliflozin (Dapa). All selected candidates signed a written consent and were then referred to the Andrology clinic for assessment for ED. The structured questionnaire (International Index of Erectile Function) was used before starting and 3 months after use of the assigned SGLT2I.

resultsBoth SGLT2Is were associated with highly significant improvement in kidney function as well as IIEF-5 (P < 0.001 in all).

conclusionSGLT2Is improve endothelial function and correct pericyte depletion induced by uremia. The postulated mechanisms of action that improve erectile function are discussed.

Indexed as

Benzhydryl CompoundsErectile DysfunctionGlucosidesPenile ErectionRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAdultAgedHumansMaleMiddle AgedTime FactorsTreatment OutcomeBenzhydryl CompoundsdapagliflozinempagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsCKDEDErectile dysfunctionSGLT2Is

Identifiers

PMID40903625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.